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asked Hypertension
nd White-Coat Hypertension
herapeutic Navigation
etween Scylla and Charybdis*
ranz H. Messerli, MD, FACC, FACP,
elia Cotiga, MD
ew York, New York
lood pressure (BP) is a very labile hemodynamic parame-
er; it varies from heartbeat to heartbeat, from morning to
vening, from winter to summer, from sleeping to awake,
nd from sitting to standing (1). The same holds true for
ny other cardiovascular hemodynamic parameter such as
eart rate, cardiac output, ejection fraction or pulmonary
edge pressure (1). However, information that is based on
nvasively obtained measurements is often considered more
eliable than information based on simple BP recording.
umerous studies have documented that BP measured by
uff carefully under standardized conditions in physicians’
ffices (2) is a powerful and reliable predictor of morbidity
nd mortality. Recent studies have documented that 24-h
mbulatory BP monitoring is even a closer surrogate end
oint for heart attack and stroke than is office BP (3,4).
ecause the correlation between 24-h ambulatory BP mea-
urement and office BP measurement is moderate at best,
ot unexpectedly there will be a significant number of
eople who are truly hypertensive but in whom the diagno-
is is missed by office BP measurements (masked hyperten-
ion). Conversely, BP may be elevated in the office but not
n ambulatory BP monitoring—an entity known to most
linicians as white-coat hypertension.
See page 508
The paper of Ohkubo et al. (5) in the present issue of the
ournal deals with the prognosis of masked hypertension and
hite-coat hypertension. The investigators followed a group
f 1,332 subjects from the general population of a small
apanese community for an average of 10 years. Patients
ere subdivided into normotensive, white-coat hyperten-
ion, masked hypertension, and sustained hypertension.
atients with white-coat hypertension had normal ambula-
ory BP monitoring values, although these were somewhat
igher than in the normotensive group. Similarly, both
ardiovascular mortality and morbidity were somewhat ele-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Hypertension Program and Division of Cardiology, St. Luke’s-Rooseveltt
ospital Center and Columbia University College of Physicians and Surgeons, New
ork, New York.ated in subjects with white-coat hypertension, although
hese levels did not reach statistical significance. In contrast,
atients with masked hypertension had a risk that was
ouble that of normotensive subjects and close to patients
ith sustained hypertension. These results were indepen-
ent of gender, use of antihypertensive medication, and
isk-factor score.
White-coat hypertension is a clinical entity familiar to
ost physicians. Various studies (6–10), including the
resent one, have shown that the risk of patients with
hite-coat hypertension is somewhat elevated but distinctly
ower than in patients who do have sustained hypertension.
espite being common, little is known how to best manage
hite-coat hypertension. Out of fear of overtreatment, some
hysicians are taking a “wait and see approach” in patients
ith white-coat hypertension. Conversely, fearing litiga-
ion, some physicians may take an overaggressive therapeu-
ic approach, which might result in hypotension and ortho-
tatic symptoms.
In contrast, masked hypertension is a much less well-
nown (but not necessarily a less common) entity that seems
o carry a distinctly more serious prognosis. This was not
nly documented in the study by Ohkubo et al. (5) but also
y Pickering et al. (11) who were the ones who proposed the
erm “masked hypertension.” The same entity has been
escribed occasionally as “reversed white-coat hypertension”
12,13). It was initially regarded as rare but was recently
ound to be present, to some extent, in as many as one-third
f the hypertensive population (12,14). Risk factors for
asked hypertension are the use of alcohol, tobacco, and
affeine as well as physical inactivity (11,15). In the PAM-
LA population, patients with masked hypertension had a
revalence of echocardiographic left ventricular hypertrophy
hat was much greater than that of normotensive subjects
16). Inappropriate target organ disease (i.e., inappropriate
or office BP levels), therefore, should trigger suspicion of
asked hypertension and motivate physicians to expose a
usceptible patient to 24-h ambulatory BP monitoring. In
he study by Ohkubo et al. (5), the fact that as many patients
ad masked hypertension as had white-coat hypertension
learly documents that this entity is often overlooked. This
s also the first prospective study that assesses the risk of
hite-coat hypertension and masked hypertension in a
epresentative sample of a general population.
The clinician should remember that it is much easier to
uspect the diagnosis of white-coat hypertension, as patients
ill usually state that their BP is normal at home. In
ontrast, masked hypertension needs to be looked for and
here are very few clinical hints as to its presence. A normal
P in the clinical setting does not mean that a patient is not
t risk from an elevated BP, which can occur at other times
f the day. This is particularly true in patients who are
reated with antihypertensive drugs that do not encompass a
ull 24-h period. Because the patient takes the medication in
he morning, BP values in the physician’s office most often
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August 2, 2005:516–7 Editorial Commentre normal but may be substantially elevated at the end of
he dosing interval (i.e., during the night and early morning
ours). Thus, in many hypertensive patients, clinic BP is
eemingly well controlled, but early morning BP, before the
atients take the medication, may be elevated, thereby
ccelerating the risk of cardiovascular events (17). For many
linicians, masked hypertension has unfortunately become a
lind spot (18) in antihypertensive therapy. Although we
ertainly cannot make a sweeping recommendation that all
atients with high BP (or normal BP on therapy) should
ndergo 24-h ambulatory BP monitoring, we believe that
he presence of inappropriate target organ disease such as
eft ventricular hypertrophy or microalbuminuria should
rouse suspicion of masked hypertension and motivate
hysicians to initiate a further work-up. As to the thera-
eutic approach, we should remember that white-coat
ypertension has a benign prognosis and can only be
vertreated; therefore, a conservative approach is probably
ustified. Conversely, masked hypertension has a much more
erious prognosis and can only be undertreated; it deserves,
herefore, a thorough evaluation and a more aggressive
herapeutic approach.
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